JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence
Ochiai, Satoru; Nomoto, Yoshihito; Yamashita, Yasufumi; Watanabe, Yui; Toyomasu, Yutaka; Kawamura, Tomoko; Takada, Akinori; Ii, Noriko; Kobayashi, Shigeki; Sakuma, Hajime;
  PDF(new window)
 Abstract
Glioblastoma (GBM) is the most common and aggressive type of primary brain neoplasm. The current standard therapy for GBM consists of maximal surgical resection within safe limits, followed by radiation therapy (RT) and chemotherapy with temozolomide. Despite advances in treatment, the prognosis of GBM remains poor. Epileptic seizure is one of the most common symptoms in patients with GBM. Valproic acid (VPA), a histone deacetylase inhibitor, is often used as an anti-epileptic drug in patients with brain neoplasms due to its effectiveness and low toxicity profile. Several in vivo and in vitro studies have indicated that VPA has radiosensitizing effects for gliomas and radioprotective influence on normal brain tissue or hippocampal neurons. The results of several retrospective studies have also indicated potential benefit to improve survival of patients with GBM. Moreover, the promising treatment results of a phase 2 trial of concurrent radiation therapy, temozolomide, and VPA for patients with GBM have been recently reported. The use of VPA in patients with GBM has thus recently receiving more attention. In this article, we review the role of VPA in radiation therapy for GBM, focusing on the clinical evidence.
 Keywords
Valproic acid;anti-epileptic drug;glioblastoma;radiation therapy;chemoradiation therapy;temozolomide;
 Language
English
 Cited by
 References
1.
Barker CA, Bishop AJ, Chang M, et al (2013). Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys, 86, 504-9. crossref(new window)

2.
Beaumont A, Whittle IR (2000). The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien), 142, 1-15. crossref(new window)

3.
Berendsen S, Varkila M, Kroonen J, et al (2015). Prognostic relevance of epilepsy at presentation in glioblastoma patients. Neuro Oncol, [Epub ahead of print]

4.
Brown SL, Kolozsvary A, Liu J, et al (2008). Histone deacetylase inhibitors protect against and mitigate the lethality of totalbody irradiation in mice. Radiat Res, 169, 474-8. crossref(new window)

5.
Chaichana KL, Parker SL, Olivi A, et al (2009). Long-term seizure outcomes in adult patients undergoing primary resection of malignant brainastrocytomas. Clinical article. J Neurosurg, 111, 282-92. crossref(new window)

6.
Chateauvieux S, Morceau F, Dicato M, et al (2010). Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol, 2010, 479364.

7.
Fu J, Shao CJ, Chen FR, et al (2010). Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines. Neuro Oncol, 12, 328-40. crossref(new window)

8.
Guthrie GD, Eljamel S (2013). Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg, 118, 859-65. crossref(new window)

9.
Hosein AN, Lim YC, Day B, et al (2015). The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neurooncol, 122, 263-71. crossref(new window)

10.
Kerkhof M, Dielemans JC, van Breemen MS, et al. (2013). Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol, 15, 961-7. crossref(new window)

11.
Krauze AV, Myrehaug SD, Chang MG, et al (2015). A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys, 92, 986-92. crossref(new window)

12.
Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. crossref(new window)

13.
Oberndorfer S, Piribauer M, Marosi C, et al (2005). P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated withstandard chemotherapy. J Neurooncol, 72, 255-60. crossref(new window)

14.
Oike T, Suzuki Y, Sugawara K, et al (2013). Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One, 8, 78943. crossref(new window)

15.
Oike T, Ogiwara H, Amornwichet N, et al (2014). Chromatinregulating proteins as targets for cancer therapy. J Radiat Res, 55, 613-28. crossref(new window)

16.
Ostrom QT, Gittleman H, Liao P, et al. (2014). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol, 16, 1-63. crossref(new window)

17.
Pont LM, Naipal K, Kloezeman JJ, et al. (2015). DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells. Cancer Lett, 356, 525-35. crossref(new window)

18.
Rosati A, Poliani PL, Todeschini A, et al (2013). Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol, 15, 618-25. crossref(new window)

19.
Rubner Y, Muth C, Strnad A, et al (2014). Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines. Radiat Oncol, 9, 89. crossref(new window)

20.
Shao CJ, Wu MW, Chen FR, et al. (2012). Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. Chin Med J, 125, 4338-43.

21.
Stark AM, van de Bergh J, Hedderich J, et al (2012). Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg, 114, 840-5. crossref(new window)

22.
Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96. crossref(new window)

23.
Stupp R, Hegi ME, Mason WP, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol, 10, 459-66. crossref(new window)

24.
Szczepanek D, Marchel A, Moskala M, et al. (2013). Efficacy of concomitant and adjuvant temozolomide in glioblastoma treatment. A multicentre randomized study. Neurol Neurochir Pol, 47, 101-8.

25.
Thotala D, Karvas RM, Engelbach JA, et al (2015). Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget, 6, 35004-22.

26.
Van Nifterik KA, Van den Berg J, Slotman BJ, et al (2012). Valproic acid sensitizes human glioma cells for temozolomide and ${\gamma}$-radiation. J Neurooncol, 107, 61-7. crossref(new window)

27.
Vecht CJ, Kerkhof M, Duran-Pena A (2014). Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist, 19, 751-9. crossref(new window)

28.
Weller M, Gorlia T, Cairncross JG, et al (2011). Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurol, 77, 1156-64. crossref(new window)

29.
Zhou Y, Xu Y, Wang H, et al (2014). Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett, 7, 203-8.

30.
Zhou Y, Niu J, Li S, et al (2015). Radioprotective effects of valproic acid, a histone deacetylase inhibitor, in the rat brain. Biomed Rep, 3, 63-9.